Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263588 · ClinicalTrials.gov registry record · Phase 2
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT00263588 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 242 participants.
The verdict
NCT00263588, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.
Interventions
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2005-12-02 |
| Est. Completion | 2018-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00263588
The ClinicalTrials.gov registry entry for NCT00263588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lapatinib is the first listed.
NCT00263588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00263588 about?
NCT00263588 is a clinical study titled "Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer". Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatini...
What is the current status of trial NCT00263588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2005-12-02. Estimated completion is 2018-03-15.
What interventions are being tested in trial NCT00263588?
The interventions under investigation include: lapatinib (DRUG).
Who is sponsoring clinical trial NCT00263588?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.